Mupirocin

Research use only, not for human use.

Mupirocin(BRL-4910A) is an antibiotic of the monoxycarbolic acid class; effective against Gram-positive bacteria, including MRSA.

Mupirocin(BRL-4910A) is an antibiotic of the monoxycarbolic acid class; effective against Gram-positive bacteria, including MRSA.(In Vitro):Mupirocin (BRL-4910A, Pseudomonic acid) (0-100 μM; 48 h) shows antibacterial effect against staphylococci, streptococci and certain gram-negative bacteria, with MIC values range from 0.06-0.25 μg/mL (MIC50 =0.12 μg/mL, MIC90 =0.25 μg/mL).Mupirocin is highly bound (95% bound) to human serum protein, thus results in activity inhibition in the presence of human serum.Mupirocin apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis.Mupirocin (2% ointment) reduces pro-inflammatory cytokines IL-1β and IL-17 level, decreases tumor necrosis factor-alpha (TNF-α) expression, and increases the leavel of vascular endothelial growth factor (VEGF).Mupirocin inhibits MS (S. epidermidis ATCC 12228), MR (S. epidermidis (Se56-99)), and VIR (S. epidermidis (Se43-98)) with MICs of 0.25, 1.26, 1.59 mg/L.(In Vivo):MRSA: Meticillin-resistant Staphylococcus aureusMupirocin (BRL-4910A, Pseudomonic acid) is well absorbed after oral and parenteral administration but serum antibiotic concentrations were short-lived as a result of extensive degradation to the antibacterially inactive metabolite, monic acid A.Mupirocin (2% ointment; external administration; twice daily; 3-6 d) decreases the total bacterial loads in the skin lesions with either topical treatment.Mupirocin (2% ointment; external administration; 4 d) alleviates MRSA-infected pressure ulcers in mice.Mupirocin (100 mg/mL; s.c.; 7 d) exerts prevention efficacy against vascular prosthetic graft infection due to Staphylococcus epidermidis.

Mupirocin (BRL-4910A, Pseudomonic acid) (0-100 μM; 48 h) shows antibacterial effect against staphylococci, streptococci and certain gram-negative bacteria, with MIC values range from 0.06-0.25 μg/mL (MIC50 =0.12 μg/mL, MIC90 =0.25 μg/mL).Mupirocin is highly bound (95% bound) to human serum protein, thus results in activity inhibition in the presence of human serum.Mupirocin apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis.Mupirocin (2% ointment) reduces pro-inflammatory cytokines IL-1β and IL-17 level, decreases tumor necrosis factor-alpha (TNF-α) expression, and increases the leavel of vascular endothelial growth factor (VEGF).Mupirocin inhibits MS (S. epidermidis ATCC 12228), MR (S. epidermidis (Se56-99)), and VIR (S. epidermidis (Se43-98)) with MICs of 0.25, 1.26, 1.59 mg/L.Note: MIC, the minimum inhibition concentration. Cell Viability Assay Cell Line:Staphylococcus aureusConcentration:0-100 μM/mL Incubation Time:24, 48 hours Result:Resulted in a 90 to 99% reduction at 24 h, with MIC values ranged from 0.12-1.0 μM/mL and MBC values ranged from 4.0-32 μM/mL at 48 h.

Mupirocin (BRL-4910A, Pseudomonic acid) is well absorbed after oral and parenteral administration but serum antibiotic concentrations were short-lived as a result of extensive degradation to the antibacterially inactive metabolite, monic acid A.Mupirocin (2% ointment; external administration; twice daily; 3-6 d) decreases the total bacterial loads in the skin lesions with either topical treatment.Mupirocin (2% ointment; external administration; 4 d) alleviates MRSA-infected pressure ulcers in mice.Mupirocin (100 mg/mL; s.c.; 7 d) exerts prevention efficacy against vascular prosthetic graft infection due to Staphylococcus epidermidis. Animal Model:MRSA skin infection model in mice (10-12 weeks old)Dosage:2% ointment Administration:External administration; twice daily; 3-6 days Result:Reduced the total bacterial loads in the skin lesions, and decreased by 2.0, 5.1 log10 CFU on day 3 and 6, respectively.Animal Model:Diabetic pressure ulcer mouse model (33.2-39.2 g)Dosage:2% ointment Administration:External administration; 4 days Result:Resulted less superficial mats of bacterial colonies, and improved histopathology evaluation.Animal Model:Adult male Wistar rats (weight 275-325 g)Dosage:Impregnated with 100 μg of mupirocin/mL; segments:1.5 cm *1 cm2 Administration:Subcutaneous implantation; 7 days Result:Resulted in preventing S. epidermidis infection of the graft in a rat model with spontaneously bound to collagen-sealed Dacron grafts.

BRL 4910A

Cell Cycle/DNA Damage

DNA/RNA Synthesis

DNA synthesis

Infection

——

12650-69-0

500.64

C26H44O9

>98% (HPLC)

Ethanol: 100 mg/mL (199.75 mM); Water: 46 mg/mL warmed (91.88 mM); DMSO: 100 mg/mL warmed (199.75 mM)

O=C(O)CCCCCCCCOC(/C=C(C)/C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@H]([C@@H](O)C)C)[C@@H](O)[C@H]1O)=O

9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid

(-20℃)

With Ice Pack

≥ 2 years